BSA
ALXN

Braun Stacey Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Braun Stacey Associates’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-38,262
Closed -$5.85M – 145
2021
Q1 		$5.85M Sell
38,262
-82,940
-68% -$12.8M 0.25% 103
2020
Q4 		$18.9M Buy
121,202
+10,434
+9% +$1.34M 0.85% 52
2020
Q3 		$12.7M Sell
110,768
-2,157
-2% -$233K 0.68% 75
2020
Q2 		$12.7M Buy
112,925
+144
+0.1% +$15.3K 0.73% 72
2020
Q1 		$10.1M Sell
112,781
-31,580
-22% -$3.1M 0.77% 63
2019
Q4 		$15.6M Buy
144,361
+19,250
+15% +$2.06M 0.87% 59
2019
Q3 		$12.3M Buy
125,111
+6,361
+5% +$717K 0.77% 75
2019
Q2 		$15.6M Buy
118,750
+4,040
+4% +$521K 1% 43
2019
Q1 		$15.5M Buy
114,710
+19,600
+21% +$2.44M 1.03% 39
2018
Q4 		$9.26M Sell
95,110
-18,962
-17% -$2.24M 0.73% 68
2018
Q3 		$15.9M Buy
114,072
+7,243
+7% +$909K 1.01% 41
2018
Q2 		$13.3M Buy
106,829
+5,771
+6% +$674K 0.9% 55
2018
Q1 		$11.3M Buy
+101,058
New +$12.1M 0.77% 73
2015
Q3 		– Sell
-101,600
Closed -$18.4M – 279
2015
Q2 		$18.4M Buy
+101,600
New +$17.5M 0.78% 56
2013
Q4 		– Sell
-2,080
Closed -$242K – 162
2013
Q3 		$242K Sell
2,080
-21,090
-91% -$2.31M 0.01% 133
2013
Q2 		$2.14M Buy
+23,170
New +$2.23M 0.13% 108

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Braun Stacey Associates's ALXN Position: Q2 2021 in Review

Braun Stacey Associates sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 38,262 shares — an estimated $5.85M sold.

Braun Stacey Associates first reported a position in ALXN in Q2 2013 and held it in 16 quarters. The position peaked at $18.9M in Q4 2020. 710 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Braun Stacey Associates reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Braun Stacey Associates sold 38,262 Alexion Pharmaceuticals shares in Q2 2021, an estimated $5.85M.
  • Braun Stacey Associates first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 16 quarters.
  • Braun Stacey Associates's Alexion Pharmaceuticals position peaked at $18.9M in Q4 2020.
  • 710 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Braun Stacey Associates's 13F filing for Q2 2021, filed 23 Jul 2021.